Preferred Label : antibodies, monoclonal;
MeSH definition : Antibodies produced by a single clone of cells.;
MeSH synonym : monoclonal antibodies; Monoclonal Antibody; Antibody, Monoclonal;
MeSH annotation : do not coordinate with ANTIBODY FORMATION for biosyn; ANTIBODY-TOXIN CONJUGATES is
available as a toxin carrier: see note there;
Wikipedia link : https://en.wikipedia.org/wiki/Monoclonal antibody;
Is substance : O;
Origin ID : D000911;
UMLS CUI : C0003250;
ATC code(s)
- Allowable qualifiers
- CISMeF manual mappings
- Indexing information
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- 4Dm2m [MeSH Supplementary Concept]
- 924-RAC [MeSH Supplementary Concept]
- ADG20 [MeSH Supplementary Concept]
- AGS67E [MeSH Supplementary Concept]
- AMG 108 [MeSH Supplementary Concept]
- AMG 139 [MeSH Supplementary Concept]
- AMG 317 [MeSH Supplementary Concept]
- AMG 403 [MeSH Supplementary Concept]
- AMG 811 [MeSH Supplementary Concept]
- ARX788 [MeSH Supplementary Concept]
- ASG-5ME [MeSH Supplementary Concept]
- ATN-658 [MeSH Supplementary Concept]
- ATR-107 [MeSH Supplementary Concept]
- BHQ880 [MeSH Supplementary Concept]
- BIIB022 [MeSH Supplementary Concept]
- BT-061 [MeSH Supplementary Concept]
- CDP 571 [MeSH Supplementary Concept]
- CMAB009 [MeSH Supplementary Concept]
- CR002 [MeSH Supplementary Concept]
- CR3022 [MeSH Supplementary Concept]
- CSL360 [MeSH Supplementary Concept]
- CT-P13 [MeSH Supplementary Concept]
- CT-P63 [MeSH Supplementary Concept]
- CT-P66 [MeSH Supplementary Concept]
- D16F7 [MeSH Supplementary Concept]
- DX-2400 [MeSH Supplementary Concept]
- DX109 [MeSH Supplementary Concept]
- EPR3864 [MeSH Supplementary Concept]
- ESBA105 [MeSH Supplementary Concept]
- HMCAZ5 [MeSH Supplementary Concept]
- IGN 311 [MeSH Supplementary Concept]
- JJ 316 [MeSH Supplementary Concept]
- JS026 [MeSH Supplementary Concept]
- JTA-009 [MeSH Supplementary Concept]
- KB004 [MeSH Supplementary Concept]
- KHK4083 [MeSH Supplementary Concept]
- KM3413 [MeSH Supplementary Concept]
- KRN-330 [MeSH Supplementary Concept]
- LDP-02 [MeSH Supplementary Concept]
- LO-CD2a [MeSH Supplementary Concept]
- LO-CD2b [MeSH Supplementary Concept]
- M290SAP [MeSH Supplementary Concept]
- MG1141A [MeSH Supplementary Concept]
- MK-4721 [MeSH Supplementary Concept]
- MM-151 [MeSH Supplementary Concept]
- NIS 793 [MeSH Supplementary Concept]
- NIS-793 [MeSH Supplementary Concept]
- RG7212 [MeSH Supplementary Concept]
- RG7652 [MeSH Supplementary Concept]
- RG7667 [MeSH Supplementary Concept]
- Reditux [MeSH Supplementary Concept]
- SAIT301 [MeSH Supplementary Concept]
- TATX-03 [MeSH Supplementary Concept]
- TB 402 [MeSH Supplementary Concept]
- TB-403 [MeSH Supplementary Concept]
- TB006 [MeSH Supplementary Concept]
- TNT003 [MeSH Supplementary Concept]
- TRL1068 [MeSH Supplementary Concept]
- ZMapp [MeSH Supplementary Concept]
- apomab [MeSH Supplementary Concept]
- See also
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
Antibodies produced by a single clone of cells.
https://www.has-sante.fr/jcms/p_3503277/fr/evkeeza-evinacumab-hypercholesterolemie-homozygote-familiale
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Homozygous Familial Hypercholesterolemia
antibodies, monoclonal
evinacumab
guidelines for drug use
package leaflet
summary of product characteristics
Product containing only evinacumab in parenteral dose form (medicinal product form)
infusions, intravenous
evaluation of the transparency committee
evkeeza
evinacumab
---
https://www.has-sante.fr/jcms/p_3503249/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antibodies, monoclonal
adult
multiple myeloma
package leaflet
summary of product characteristics
guidelines for drug use
recurrence
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Progressive Neoplastic Disease
evaluation of the transparency committee
Elranatamab
---
https://papyrus.bib.umontreal.ca/xmlui/handle/1866/32798
2024
Canada
dissertations, academic
attention
monoclonal antibody
Monoclonal Antibody
Apply
immunotherapy
immunotherapy, nos
Applicator
antibodies, monoclonal
Immunotherapy
Monoclonal Antibody (Therapeutic)
Apply
---
https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
drug approval
Elranatamab
Elranatamab
multiple myeloma
recurrence
Progressive Neoplastic Disease
Triple-Class Refractory Multiple Myeloma
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Recurrent Multiple Myeloma
antibodies, monoclonal
antibodies, monoclonal
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
injections, subcutaneous
bispecific monoclonal antibodies
bispecific monoclonal antibodies
Immune Effector Cell Associated Neurotoxicity Syndrome
Elranatamab
Cytokine Release Syndrome
continuity of patient care
---
https://ansm.sante.fr/actualites/modification-des-conditions-de-prescription-et-de-delivrance-de-certaines-biotherapies-utilisees-dans-le-traitement-de-maladies-inflammatoires-chroniques
2024
false
false
false
France
French
guidelines for drug use
injections, subcutaneous
Interleukin Inhibitors
immunosuppressive agents
biological therapy
general practice
antibodies, monoclonal
immunoconjugates
Tumor Necrosis Factor Inhibitors
Chronic inflammatory disorder (disorder)
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/posologie-des-anticorps-monoclonaux-ciblant-le-pd-1-ou-le-pd-l1.html
2023
false
false
false
Canada
programmed cell death 1 receptor
Nivolumab
pembrolizumab
antibodies, monoclonal, humanized
atezolizumab
avelumab
cemiplimab
durvalumab
guidelines for drug use
antibodies, monoclonal
antibodies, monoclonal
B7-H1 Antigen
---
https://www.has-sante.fr/jcms/p_3411556/fr/elranatamab-pfizer-elranatamab-myelome-multiple
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
Elranatamab
antibodies, monoclonal
adult
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
guidelines for drug use
injections, subcutaneous
evaluation of the transparency committee
multiple myeloma
---
https://www.cmg.fr/wp-content/uploads/2023/10/Fiche-Nirsevimab-actualisee-20230928.pdf
2023
France
scientific and technical information
monoclonal antibody
respiratory syncytial viruses
Chuvash Language
bronchiolitis
nirsevimab
infant
nirsevimab
bronchiolitis, nos
Verbal Rating Scale
Vienna Rectoscopy Score
Prevention
Bronchiolitis
antibodies, monoclonal
Nirsevimab
Prevention Study
blood group antibody vr
Use
Preventive Intervention
---
https://lecmg.fr/prevention-des-bronchiolites-a-vrs-des-nourrissons-par-lutilisation-dun-anticorps-monoclonal-au-cabinet-le-nirsevimab-beyfortus/
2023
false
false
false
France
scientific and technical information
antibodies, monoclonal
blood group antibody vr
bronchiolitis, nos
infant
Monoclonal antibodies
Monoclonal antibodies
bronchiolitis
nirsevimab
respiratory syncytial viruses
monoclonal antibody
Bronchiolitis
nirsevimab
---
https://www.cbip.be/fr/articles/3975?folia=3941
2023
false
false
false
Belgium
French
journal article
antibodies, monoclonal
Lecanemab
alzheimer disease
lecanemab
---
https://ansm.sante.fr/tableau-acces-derogatoire/elranatamab
2023
false
false
false
France
French
Elranatamab
summary of product characteristics
package leaflet
guidelines for drug use
multiple myeloma
adult
Relapsed/refractory multiple myeloma
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
antibodies, monoclonal
---
https://papyrus.bib.umontreal.ca/xmlui/handle/1866/28309
2023
Canada
educational course
Theories
Theories
Theories
Theories
Theories
Theories
antibodies, monoclonal
immunotherapy
Theories
Theories
Applications
Theories
Theories
Theories
Monoclonal antibodies
Immunotherapy
Theories
Theories
attention
immunotherapy, nos
Applications
Theories
Theories
Theories
Monoclonal antibodies
Theories
Theories
Theories
Theories
Theories
Theories
Applications
monoclonal antibody
---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2023
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab
---
https://www.has-sante.fr/jcms/p_3424344/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
adult
antibodies, monoclonal
Teclistamab
injections, subcutaneous
Antineoplastic Agents, Immunological
teclistamab
evaluation of the transparency committee
multiple myeloma
---
https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/tout-savoir-sur-le-covid-19/article/traitement-par-anticorps-monoclonaux
2022
false
false
false
France
pneumonia, viral
coronavirus infections
scientific and technical information
coronavirus
Monoclonal antibodies
coronavirus, nos
monoclonal antibody
Monoclonal antibodies
antibodies, monoclonal
pandemics
COVID-19
---
https://ansm.sante.fr/tableau-marr/avelumab
2022
false
false
false
France
French
immune system diseases
avelumab
avelumab
Drug-Related side effects and adverse reactions
Infusion related reaction
signs and symptoms
patient education handout
infusions, intravenous
avelumab
risk management
immune system diseases
antineoplastic agents
antineoplastic agents
Drug-Related side effects and adverse reactions
immune system diseases
guidelines for drug use
patients guideline
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli
2022
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Teclistamab
Teclistamab
antibodies, monoclonal
antibodies, monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
teclistamab
injections, subcutaneous
drug interactions
pregnancy
breast feeding
Triple-Class Refractory Multiple Myeloma
recurrence
product surveillance, postmarketing
bispecific monoclonal antibodies
bispecific monoclonal antibodies
b-cell maturation antigen
CD3 Complex
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Faricimab
Faricimab
faricimab
antibodies, monoclonal
antibodies, monoclonal
wet macular degeneration
intravitreal injections
vascular endothelial growth factor a
Angiopoietin-2
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
macular edema
diabetes complications
---
https://recalls-rappels.canada.ca/fr/avis-rappel/evusheld-tixagevimab-et-cilgavimab-injectables-risque-echec-prophylaxie-ou-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug resistance, viral
cilgavimab and tixagevimab drug combination
drug combinations
tixagevimab
cilgavimab
tixagevimab and cilgavimab
antibodies, monoclonal
antiviral agents
Evusheld
injections, intramuscular
COVID-19
COVID-19
Pre-Exposure Prophylaxis
SARS-CoV-2 variants
---
https://www.has-sante.fr/jcms/p_3368649/fr/tecvayli-teclistamab-myelome-multiple
2022
false
false
false
France
multiple myeloma
antibodies, monoclonal
Teclistamab
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma
injections, subcutaneous
Antineoplastic Agents, Immunological
teclistamab
evaluation of the transparency committee
---
https://www.cochrane.org/fr/CD014945/HAEMATOL_les-anticorps-monoclonaux-specifiques-de-la-covid-19-fabriques-en-laboratoire-sont-ils-efficaces
2022
false
false
false
United Kingdom
COVID-19
cilgavimab and tixagevimab drug combination
casirivimab and imdevimab drug combination
bamlanivimab
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
review of literature
french abstract
antibodies, monoclonal
---
https://presse.inserm.fr/covid-19-identification-danticorps-monoclonaux-neutralisants-a-large-spectre/45440/
2022
false
false
false
France
COVID-19
popular works
monoclonal antibody
widening, nos
antibodies, neutralizing
Broadly Neutralizing Antibodies
Monoclonal antibodies
antibodies, monoclonal
Identification, Psychological
De-Identification
Monoclonal antibodies
---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs-u_2022_49_-_evusheld.pdf
2022
false
false
false
France
COVID-19
guideline
tixagevimab
monoclonal antibody
tixagevimab
antibodies, monoclonal
Monoclonal antibodies
Evusheld
laboratories
patient care management
Monoclonal antibodies
---
https://www.has-sante.fr/jcms/p_3313574/fr/praluent-alirocumab
2022
false
false
false
France
antibodies, monoclonal
antibodies, monoclonal, humanized
insurance, health, reimbursement
hydroxymethylglutaryl-coa reductase inhibitors
Ezetimibe
adult
Heterozygous familial hypercholesterolemia
Atherosclerotic cardiovascular disease
evaluation of the transparency committee
alirocumab
---
https://www.has-sante.fr/jcms/p_3313603/fr/repatha-evolocumab
2022
false
false
false
France
insurance, health, reimbursement
antibodies, monoclonal
antibodies, monoclonal, humanized
hydroxymethylglutaryl-coa reductase inhibitors
Ezetimibe
adult
Atherosclerotic cardiovascular disease
Heterozygous familial hypercholesterolemia
evaluation of the transparency committee
evolocumab
---
https://conseil-scientifique.public.lu/fr/publications/covid-19/acmc-6-2022.html
2022
false
false
false
France
COVID-19
practice guideline
monoclonal antibody
patient care management
Monoclonal antibodies
antibodies, monoclonal
Monoclonal antibodies
pneumonia, viral
coronavirus infections
pandemics
---
https://ansm.sante.fr/actualites/traitements-par-anticorps-monoclonaux-actuellement-disponibles-contre-la-covid-19-et-utilisation-selon-les-variants
2022
false
false
false
France
French
guidelines for drug use
COVID-19
COVID-19
antibodies, monoclonal
Post-Exposure prophylaxis
Pre-Exposure Prophylaxis
casirivimab and imdevimab drug combination
cilgavimab and tixagevimab drug combination
SARS-CoV-2 variants
casirivimab and imdevimab drug combination
---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs-urgent__2022-03_acm_.pdf
2022
false
false
false
France
COVID-19
public health guidelines
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3272286/fr/keytruda-pembrolizumab-cancer-colorectal-metastatique
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
pembrolizumab
colorectal neoplasms
neoplasm metastasis
Metastatic malignant neoplasm to colon and/or rectum (disorder)
adult
Antineoplastic Agents, Immunological
Unresectable Colorectal Carcinoma
infusions, intravenous
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3273465/fr/crysvita-burosumab-hypophosphatemie-liee-a-l-x-pediatrie-et-adultes
2021
false
false
false
France
burosumab
treatment outcome
insurance, health, reimbursement
burosumab
injections, subcutaneous
rickets, X-Linked hypophosphatemic
adult
child
adolescent
rare diseases
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal, humanized
familial hypophosphatemic rickets
antibodies, monoclonal
---
https://cadth.ca/fr/enfortumab-vedotine
2021
false
false
false
Canada
French
English
enfortumab vedotin
drug information
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
enfortumab vedotin
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3273739/fr/skyrizi-risankizumab
2021
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
risankizumab
Product containing only risankizumab in parenteral dose form (medicinal product form)
antibodies, monoclonal
---
https://ansm.sante.fr/tableau-atu-rtu/adtralza-150-mg-solution-injectable-en-seringue-preremplie
2021
false
false
false
France
French
tralokinumab
tralokinumab
guidelines for drug use
summary of product characteristics
package leaflet
adult
dermatitis, atopic
antibodies, monoclonal
antibodies, monoclonal
---
https://ansm.sante.fr/tableau-atu-rtu/atezolizumab-840-mg-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
guidelines for drug use
antineoplastic combined chemotherapy protocols
atezolizumab
Albumin-Bound Paclitaxel
paclitaxel
Atezolizumab/Nab-paclitaxel Regimen
adult
triple negative breast neoplasms
summary of product characteristics
package leaflet
infusions, intravenous
atezolizumab
antineoplastic agents
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/tableau-atu-rtu/anifrolumab-300-mg-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
infusions, intravenous
anifrolumab
anifrolumab
guidelines for drug use
summary of product characteristics
package leaflet
adult
lupus erythematosus, systemic
antibodies, monoclonal, humanized
interferon alpha-beta receptor chain 1
IFNAR1 protein, human
anifrolumab
receptor, interferon alpha-beta
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tralokinumab
tralokinumab
drug approval
europe
tralokinumab
adult
dermatitis, atopic
injections, subcutaneous
Interleukin-13
drug monitoring
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal
---
https://solidarites-sante.gouv.fr/IMG/pdf/anticorps_monoclonaux_parcourspds-bitherapie_curatif_pf2.pdf
https://solidarites-sante.gouv.fr/IMG/pdf/dgs-urgent_85_anticorps_monoclonal_bitherapie.pdf
https://solidarites-sante.gouv.fr/IMG/pdf/anticorps_monoclonaux_parcourspds-bitherapieroche_prophylaxie_pf1.pdf
2021
false
false
false
France
casirivimab and imdevimab drug combination
guideline
COVID-19
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal
product form)
health facilities
patients
casirivimab and imdevimab drug combination
snacks
indicators
casirivimab
Maladjustment
has patient
monoclonal antibody
indicators and reagents
prophylactic treatment, nos
risk
antibodies, monoclonal
Monoclonal antibodies
hazardous substances
traction
indication of
imdevimab
Monoclonal antibodies
---
https://solidarites-sante.gouv.fr/IMG/pdf/20210817_anticorps_monoclonaux_parcourspds-bitherapieroche_prophylaxie.pdf
2021
false
false
false
France
algorithms
guideline
COVID-19
orientation, nos
prophylactic treatment, nos
Monoclonal antibodies
orientation
Monoclonal antibodies
monoclonal antibody
antibodies, monoclonal
---
https://www.cbip.be/fr/articles/3662?folia=3658
2021
false
false
false
Belgium
French
journal article
drug information
antibodies, monoclonal, humanized
migraine disorders
antibodies, monoclonal
belgium
calcitonin gene-related peptide
erenumab
fremanezumab
galcanezumab
---
https://www.cochrane.org/fr/CD013825/HAEMATOL_les-anticorps-monoclonaux-specifiques-de-la-covid-19-fabriques-en-laboratoire-constituent-ils-un
2021
false
false
false
United Kingdom
review of literature
french abstract
COVID-19
antibodies, monoclonal
---
https://www.infectiologie.com/fr/actualites/ac-en-prophylaxie-primaire-du-covid_-n.html
2021
France
guideline
Betacoronavirus
COVID-19
administration
indicators and reagents
antibodies, monoclonal
Administration
indication of
Monoclonal antibodies
indicators
population
organization and administration
monoclonal antibody
Monoclonal antibodies
SARS-CoV-2
---
https://www.has-sante.fr/jcms/p_3287082/fr/syncardia-tah-t-70cc
2021
France
health technology assessment
antineoplastic combined chemotherapy protocols
cyclophosphamide
doxorubicin
medroxyprogesterone
middle cerebral artery
both cardiac ventricles
ACM protocol
antibodies, monoclonal
assisted circulation
---
https://ansm.sante.fr/actualites/evusheld-une-nouvelle-bitherapie-danticorps-monoclonaux-contre-la-covid-19-autorisee-en-acces-precoce
2021
false
false
false
France
French
drug information
COVID-19
Pre-Exposure Prophylaxis
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab
antibodies, neutralizing
drug combinations
antibodies, monoclonal
antiviral agents
injections, intramuscular
treatment outcome
patient safety
adult
summary of product characteristics
package leaflet
---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs_urgent_2021_129_astra_zeneca_traitement_.pdf
2021
France
COVID-19
COVID-19 Vaccines
scientific and technical information
tixagevimab
Set, Psychology
devices
monoclonal antibody
Monoclonal antibodies
laboratories
antibodies, monoclonal
device, nos
Monoclonal antibodies
tixagevimab
---
https://www.has-sante.fr/jcms/p_3223297/fr/sarclisa
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
isatuximab
adult
antineoplastic combined chemotherapy protocols
multiple myeloma
Dexamethasone/Isatuximab/Pomalidomide Regimen
dexamethasone
pomalidomide
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
isatuximab
isatuximab
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
thalidomide
thalidomide
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3233061/fr/cosentyx-enfant
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
secukinumab
psoriasis
child
adolescent
injections, subcutaneous
guidelines for drug use
Interleukin-17
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.academie-medecine.fr/les-anticorps-monoclonaux-anti-sars-cov-2-une-opportunite-a-saisir/
2021
false
false
false
France
coronavirus infections
pneumonia, viral
antibodies, monoclonal
SARS Coronavirus 2 Antibody
scientific and technical information
pneumonia, viral
coronavirus infections
pandemics
COVID-19
---
https://www.has-sante.fr/jcms/p_3236700/fr/crysvita
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
burosumab
rare diseases
adolescent
adult
X-linked hypophosphatemia
familial hypophosphatemic rickets
burosumab
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3238105/fr/praluent
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
alirocumab
mixed dyslipidemia
hypercholesterolemia
alirocumab
dyslipidemias
Atherosclerotic Cardiovascular Disease
Primary hypercholesterolemia (disorder)
injections, subcutaneous
antibodies, monoclonal
---
https://solidarites-sante.gouv.fr/IMG/pdf/anticorps_monoclonaux_fichepreventionpatient_2.pdf
2021
false
false
false
France
pneumonia, viral
coronavirus infections
popular works
monoclonal antibody
antibodies, monoclonal
blood group antibody ia
Monoclonal antibodies
Monoclonal antibodies
pandemics
COVID-19
---
https://solidarites-sante.gouv.fr/IMG/pdf/20210226_anticorps_monoclonaux_parcourspds-bam.pdf
2021
false
false
false
France
pneumonia, viral
coronavirus infections
scientific and technical information
Monoclonal antibodies
antibodies, monoclonal
monoclonal antibody
case management
Monoclonal antibodies
has patient
orientation
orientation, nos
pandemics
COVID-19
---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs_urgent_n2021_22_bamlanivimab_erratum_.pdf
2021
false
false
false
France
pneumonia, viral
coronavirus infections
bamlanivimab
drug information
hazardous substances
case management
Monoclonal antibodies
antibodies, monoclonal
Monoclonal antibodies
health facilities
risk-taking
monoclonal antibody
has patient
pandemics
COVID-19
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3239200/fr/imfinzi
2021
false
false
false
France
durvalumab
carcinoma, non-small-cell lung
bronchial neoplasms
adult
infusions, intravenous
antineoplastic agents
continuity of patient care
drug monitoring
guidelines for drug use
treatment outcome
insurance, health, reimbursement
survival analysis
durvalumab
antineoplastic agents
evaluation of the transparency committee
durvalumab
antibodies, monoclonal
antibodies, monoclonal
---
https://solidarites-sante.gouv.fr/IMG/pdf/reponse_de_l_anrs_maladies_infectieuses_emergentes_au_ministere_des_solidarites_et_de_la_sante_concernant_la_saisine_.pdf
https://solidarites-sante.gouv.fr/IMG/pdf/addendum_a_la_reponse_de_l_anrs_maladies_infectieuses_emergentes_au_ministere_des_solidarites_et_de_la_sante_concernant_la_saisine.pdf
2021
France
pneumonia, viral
coronavirus infections
drug evaluation
Monoclonal antibodies
Antiviral agents
monoclonal antibody
Monoclonal antibodies
antibodies, viral
evaluation studies as topic
blood group antibody covas
Severe acute respiratory syndrome-related coronavirus
antibodies, monoclonal
Antiviral drugs
pandemics
COVID-19
---
https://www.has-sante.fr/jcms/p_3240699/fr/tecentriq-carcinome-hepatocellulaire-chc
2021
false
false
false
France
atezolizumab
insurance, health, reimbursement
treatment outcome
atezolizumab
carcinoma, hepatocellular
atezolizumab
antineoplastic combined chemotherapy protocols
Bevacizumab
adult
Atezolizumab/Bevacizumab Regimen
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Advanced Adult Hepatocellular Carcinoma
continuity of patient care
infusions, intravenous
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3240424/fr/cosentyx
2021
false
false
false
France
French
secukinumab
secukinumab
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3240240/fr/cosentyx
2021
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
secukinumab
secukinumab
arthritis, psoriatic
Non-radiographic axial spondyloarthritis
spondylitis, ankylosing
psoriasis
adult
child
adolescent
injections, subcutaneous
antibodies, monoclonal
---
https://www.ansm.sante.fr/actualites/anticorps-monoclonaux-lansm-permet-lutilisation-en-acces-precoce-de-deux-bitherapies-contre-la-covid-19
2021
false
false
false
France
French
scientific and technical information
drug information
antibodies, monoclonal
adult
Casirivimab/Imdevimab
Casirivimab
Imdevimab
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
Bamlanivimab
Etesevimab
aged
spike glycoprotein, coronavirus
france
drug monitoring
risk
drug combinations
casirivimab and imdevimab drug combination
COVID-19
COVID-19
casirivimab
imdevimab
casirivimab and imdevimab
drug combinations
antibodies, monoclonal, humanized
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal
product form)
casirivimab and imdevimab drug combination
---
https://solidarites-sante.gouv.fr/IMG/pdf/dgs_urgent_2021-30_bitherapie_anticorps_monoclonaux.pdf
2021
France
coronavirus infections
pneumonia, viral
scientific and technical information
Monoclonal antibodies
has patient
monoclonal antibody
Monoclonal antibodies
health facilities
case management
hazardous substances
risk-taking
antibodies, monoclonal
pandemics
COVID-19
---
https://www.has-sante.fr/jcms/p_3242177/fr/imfinzi-cancer-bronchique-a-petites-cellules-a-un-stade-etendu-cbpc-se
2021
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
durvalumab
antineoplastic agents
infusions, intravenous
small cell lung carcinoma
bronchial neoplasms
antineoplastic combined chemotherapy protocols
Carboplatin/Durvalumab/Etoposide Regimen
Cisplatin/Durvalumab/Etoposide Regimen
cisplatin
etoposide
carboplatin
adult
Extensive Stage Lung Small Cell Carcinoma
B7-H1 Antigen
durvalumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3243905/fr/evenity
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
romosozumab
guidelines for drug use
osteoporosis, postmenopausal
osteoporotic fractures
aged
risk assessment
injections, subcutaneous
evenity
Product containing only romosozumab in parenteral dose form (medicinal product form)
evaluation of the transparency committee
romosozumab
romosozumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3243896/fr/bavencio-carcinome-urothelial
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
avelumab
avelumab
infusions, intravenous
Antineoplastic Agents, Immunological
adult
neoplasm metastasis
Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma
evaluation of the transparency committee
antibodies, monoclonal
---
https://splf.fr/wp-content/uploads/2021/03/SPILF-Place-des-combinaisons-danticorps-monoclonaux-dans-le-traitement-des-infections-a-SARS-COV2-23-03-21.pdf
2021
false
false
false
France
coronavirus infections
pneumonia, viral
etesevimab
scientific and technical information
infectious disease, nos
Infections
Infectious disease
monoclonal antibody
Monoclonal antibodies
antibodies, monoclonal
Monoclonal antibodies
combined
COVID-19
---
https://www.has-sante.fr/jcms/p_3245422/fr/keytruda-cbnpc-2eme-ligne
2021
false
false
false
France
pembrolizumab
Antineoplastic Agents, Immunological
insurance, health, reimbursement
treatment outcome
adult
bronchial neoplasms
carcinoma, non-small-cell lung
PD-L1 Positive
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.cadth.ca/fr/tralokinumab
2021
false
false
false
Canada
French
insurance, health, reimbursement
dermatitis, atopic
drug information
adult
tralokinumab
antibodies, monoclonal
---
https://ansm.sante.fr/informations-de-securite/tecentriq-atezolizumab-risque-de-reactions-cutanees-severes
2021
false
false
false
France
French
pharmacovigilance note
atezolizumab
risk
stevens-johnson syndrome
epidermal necrolysis, toxic
drug hypersensitivity syndrome
atezolizumab
antineoplastic agents
antibodies, monoclonal
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=997
2021
France
coronavirus infections
pneumonia, viral
practice guideline
Monoclonal antibodies
health planning guidelines
therapeutics
monoclonal antibody
tocilizumab
Monoclonal antibodies
antibodies, monoclonal
Treatments
tocilizumab
Treatments
therapeutics
antibodies, monoclonal, humanized
pandemics
COVID-19
---
https://www.ema.europa.eu/en/medicines/human/EPAR/gamifant
2021
false
false
false
Netherlands
French
English
treatment outcome
Emapalumab
antibodies, neutralizing
antibodies, monoclonal
syndication feed
summary of product characteristics
package leaflet
drug evaluation
child
adolescent
lymphohistiocytosis, hemophagocytic
familial hemophagocytic lymphocytosis
infusions, intravenous
orphan drug production
emapalumab
europe
Gamifant
Emapalumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
drug approval
ofatumumab
ofatumumab
ofatumumab
adult
multiple sclerosis, relapsing-remitting
injections, subcutaneous
Anti-CD20 Monoclonal Antibody
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
antigens, CD20
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3264981/fr/adakveo-crizanlizumab
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
crizanlizumab
infusions, intravenous
crizanlizumab
anemia, sickle cell
Vaso-Occlusive Crisis
antibodies, monoclonal, humanized
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3271021/fr/tremfya-guselkumab-rhumatisme-psoriasique
2021
false
false
false
France
evaluation of the transparency committee
guselkumab
antibodies, monoclonal
antibodies, monoclonal, humanized
treatment outcome
insurance, health, reimbursement
arthritis, psoriatic
adult
drug therapy, combination
methotrexate
guselkumab
injections, subcutaneous
Interleukin-23
---
https://www.has-sante.fr/jcms/p_3112911/fr/keytruda
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
pembrolizumab
pembrolizumab
Metastatic Lung Non-Small Cell Squamous Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
carcinoma, non-small-cell lung
adult
carcinoma, squamous cell
carboplatin
paclitaxel
Albumin-Bound Paclitaxel
infusions, intravenous
Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen
Carboplatin/Paclitaxel/Pembrolizumab Regimen
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/libtayo-cancer-cutane-5090.html
2020
false
false
false
Canada
French
drug evaluation
cemiplimab
Locally Advanced Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
carcinoma, squamous cell
skin neoplasms
antibodies, monoclonal
---
https://www.snfge.org/actualite/covid-19-et-pathologies-inflammatoires-chroniques
https://www.snfge.org/sites/default/files/SNFGE/information_inserm_is_covid-19_10_mars_2020.pdf
2020
false
false
false
France
coronavirus infections
immunosuppressive agents
antibodies, monoclonal
inflammatory bowel diseases
glucocorticoids
guidelines
COVID-19
chronic disease
pneumonia, viral
COVID-19
---
https://www.has-sante.fr/jcms/p_3162058/fr/tremfya
2020
false
false
false
France
guselkumab
guselkumab
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
psoriasis
adult
chronic disease
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/c_2906433/fr/keytruda-cancer-bronchique-non-a-petites-cellules-1ere-ligne
2020
false
false
false
France
pembrolizumab
antineoplastic combined chemotherapy protocols
Pemetrexed
platinum compounds
bronchial neoplasms
carcinoma, non-small-cell lung
adult
neoplasm metastasis
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3166985/fr/libtayo
2020
false
false
false
France
infusions, intravenous
treatment outcome
cemiplimab
cemiplimab
Antineoplastic Agents, Immunological
insurance, health, reimbursement
neoplasm metastasis
Metastatic Skin Squamous Cell Carcinoma
Locally Advanced Skin Squamous Cell Carcinoma
adult
skin neoplasms
carcinoma, squamous cell
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3167438/fr/tecentriq-cancer-du-sein-triple-negatif-carcinome-urothelial-et-cbnpc
2020
false
false
false
France
atezolizumab
guidelines for drug use
triple negative breast neoplasms
infusions, intravenous
antineoplastic agents
treatment outcome
insurance, health, reimbursement
carcinoma, non-small-cell lung
urologic neoplasms
Urothelial Carcinoma
adult
neoplasm metastasis
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3165896/fr/bavencio
2020
false
false
false
France
treatment outcome
avelumab
infusions, intravenous
antineoplastic agents
avelumab
insurance, health, reimbursement
adult
neoplasm metastasis
carcinoma, merkel cell
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3178278/fr/dupixent
2020
false
false
false
France
dupilumab
evaluation of the transparency committee
dupilumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/evenity
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
romosozumab
osteoporotic fractures
osteoporosis, postmenopausal
adult
aged
injections, subcutaneous
SOST protein, human
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
evenity
Product containing only romosozumab in parenteral dose form (medicinal product form)
romosozumab
romosozumab
antibodies, monoclonal
antibodies, monoclonal
genetic markers
bone morphogenetic proteins
---
https://www.has-sante.fr/jcms/p_3183518/fr/darzalex
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
daratumumab
daratumumab
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
Bortezomib
thalidomide
dexamethasone
antineoplastic agents
infusions, intravenous
peripheral blood stem cell transplantation
transplantation, autologous
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184445/fr/trogarzo
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
ibalizumab
ibalizumab
ibalizumab
anti-hiv agents
hiv infections
HIV-1
adult
drug resistance, multiple, viral
infusions, intravenous
multiresistant HIV-1 infection
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184911/fr/tecentriq-cbpc
2020
false
false
false
France
antineoplastic agents
atezolizumab
adult
antineoplastic combined chemotherapy protocols
etoposide
carboplatin
bronchial neoplasms
small cell lung carcinoma
infusions, intravenous
insurance, health, reimbursement
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184677/fr/keytruda-cancer-du-rein
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
carcinoma, renal cell
antineoplastic combined chemotherapy protocols
Axitinib
Antineoplastic Agents, Immunological
pembrolizumab
infusions, intravenous
survival analysis
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
antineoplastic combined chemotherapy protocols
pomalidomide
dexamethasone
antineoplastic agents
antineoplastic agents
multiple myeloma
adult
infusions, intravenous
CD38 protein, human
product surveillance, postmarketing
recurrence
aged
pregnancy
breast feeding
isatuximab
survival analysis
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Dexamethasone/Isatuximab/Pomalidomide Regimen
isatuximab
isatuximab
antibodies, monoclonal
antibodies, monoclonal
thalidomide
thalidomide
membrane glycoproteins
ADP-ribosyl Cyclase 1
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3190309/fr/ilumetri
2020
false
false
false
France
tildrakizumab
tildrakizumab
tildrakizumab
treatment outcome
insurance, health, reimbursement
adult
chronic disease
psoriasis
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184665/fr/bavencio-rein
2020
false
false
false
France
avelumab
avelumab
antineoplastic combined chemotherapy protocols
Axitinib
antineoplastic agents
insurance, health, reimbursement
treatment outcome
clear cell renal cell carcinoma
Avelumab/Axitinib Regimen
prognosis
survival analysis
Avelumab/Axitinib Regimen
evaluation of the transparency committee
carcinoma, renal cell
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3190303/fr/keytruda-carcinome-epidermoide-de-la-tete-et-du-cou-cetec
2020
false
false
false
France
French
evaluation of the transparency committee
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
pembrolizumab
pembrolizumab
pembrolizumab
adult
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
Squamous Cell Carcinoma of Head and Neck
neoplasm metastasis
neoplasm recurrence, local
B7-H1 Antigen
head and neck neoplasms
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3191463/fr/emgality
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
galcanezumab
galcanezumab
galcanezumab
injections, subcutaneous
antibodies, monoclonal, humanized
migraine disorders
Product containing only galcanezumab in parenteral dose form (medicinal product form)
antibodies, monoclonal, humanized
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3196691/fr/polivy
2020
false
false
false
France
French
evaluation of the transparency committee
polatuzumab vedotin
infusions, intravenous
polatuzumab vedotin
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
Rituximab
Bendamustine Hydrochloride
adult
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
antibodies, monoclonal
immunoconjugates
---
https://pgtmsite.files.wordpress.com/2024/01/ad-anti-pd-1_final-corr.pdf
2020
false
false
false
Canada
technical report
quebec
pembrolizumab
has patient
Portal vein air
nivolumab
patients
neoplasm, malignant
cancer
Nivolumab
hospitals, university
neoplasms
pembrolizumab
Cancer
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_INESSS_biotherapie_IL-1.pdf
2020
false
false
true
Canada
pneumonia, viral
coronavirus infections
Interleukin-6
quebec
siltuximab
siltuximab
tocilizumab
tocilizumab
sarilumab
sarilumab
treatment outcome
guideline
receptors, interleukin-6
biological therapy
interleukin-6
pneumonia, viral
coronavirus infections
pandemics
antibodies, monoclonal
antibodies, monoclonal, humanized
COVID-19
---
https://www.has-sante.fr/jcms/p_3200943/fr/darzalex
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
multiple myeloma
antineoplastic agents
daratumumab
survival analysis
injections, subcutaneous
Product containing only daratumumab in parenteral dose form (medicinal product form)
evaluation of the transparency committee
daratumumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/choix-de-la-posologie-du-nivolumab-et-du-pembrolizumab.html
2020
Canada
guidelines for drug use
Nivolumab
pembrolizumab
pembrolizumab
nivolumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3202357/fr/ajovy
2020
false
false
false
France
fremanezumab
fremanezumab
treatment outcome
insurance, health, reimbursement
adult
migraine disorders
Product containing only fremanezumab in parenteral dose form (medicinal product form)
migraine disorders
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Nivolumab_Pembrolizumab_Outil_Posologies-.pdf
2020
Canada
drug evaluation
pembrolizumab
Nivolumab
nivolumab
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3211082/fr/cosentyx-spondyloarthrite-axiale-non-radiographique
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
injections, subcutaneous
Interleukin-17
secukinumab
adult
Non-radiographic axial spondyloarthritis
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3214273/fr/tecentriq
2020
false
false
false
France
atezolizumab
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen
bronchial neoplasms
carcinoma, non-small-cell lung
antineoplastic agents
neoplasm metastasis
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/obiltoxaximab-sfl
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
obiltoxaximab
obiltoxaximab
obiltoxaximab
anthrax
orphan drug production
drug therapy, combination
inhalation anthrax
bacillus anthracis
infusions, intravenous
anthrax protective antigen
product surveillance, postmarketing
Post-Exposure prophylaxis
adult
child
aged
inhalation anthrax
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
anthrax toxin
antigens, bacterial
bacterial toxins
antibodies, monoclonal
antitoxins
antibodies, monoclonal
antitoxins
respiratory tract infections
anthrax
respiratory tract infections
---
https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Crizanlizumab
Crizanlizumab
drug approval
europe
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
crizanlizumab
orphan drug production
pain
young adult
adult
anemia, sickle cell
drug therapy, combination
hydroxyurea
infusions, intravenous
P-Selectin
product surveillance, postmarketing
Vaso-Occlusive Crisis
aged
pregnancy
breast feeding
drug evaluation, preclinical
crizanlizumab
crizanlizumab
antibodies, monoclonal
antibodies, monoclonal
---
https://covid.cadth.ca/fr/traitement-fr/groupe-consultatif-sur-la-mise-en-oeuvre-du-bamlanivimab/
https://covid.cadth.ca/fr/traitement-fr/le-bamlanivimab-dans-le-traitement-de-la-covid-19-evaluation-critique-de-lanalyse-intermediaire-de-lessai-blase-1/
2020
false
false
false
Canada
French
English
drug information
drug approval
canada
antibodies, monoclonal
adult
adolescent
drug monitoring
continuity of patient care
technical report
Evidence-Based medicine
bamlanivimab
COVID-19
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/tableau-atu-rtu/dostarlimab-50-mg-ml-solution-pour-perfusion
2020
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
Dostarlimab
dostarlimab
infusions, intravenous
adult
endometrial neoplasms
antibodies, monoclonal
Antineoplastic Agents, Immunological
microsatellite instability
Mismatch Repair Deficiency
Microsatellite instability-high solid malignant tumor (disorder)
---
https://www.has-sante.fr/jcms/p_3222371/fr/ilaris-maladie-de-still
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
canakinumab
Interleukin-1beta
injections, subcutaneous
Still's disease, Adult-Onset
guidelines for drug use
adult
evaluation of the transparency committee
canakinumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/polivy
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
polatuzumab vedotin
polatuzumab vedotin
orphan drug production
antineoplastic agents
antineoplastic agents
polatuzumab vedotin
antineoplastic combined chemotherapy protocols
Rituximab
Bendamustine Hydrochloride
adult
lymphoma, large B-Cell, diffuse
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal
immunoconjugates
antibodies, monoclonal
immunoconjugates
---
https://www.has-sante.fr/portail/jcms/c_2892906/fr/keytruda
2019
false
false
false
France
French
treatment outcome
evaluation of the transparency committee
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.cochrane.org/fr/CD012804/ustekinumab-et-briakinumab-pour-le-traitement-de-la-maladie-de-crohn-inactive
2019
France
United Kingdom
review of literature
french abstract
crohn disease
Diseases
briakinumab
Disease
Ustekinumab
crohn's disease, nos
antibodies, monoclonal
---
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/68974a-fra.php
2019
false
false
false
Canada
French
English
drug information
prescription, nos
clinical trials as topic
Lartruvo
clinical trial
olaratumab
dataset
clinical trial
dataset
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2808583/fr/darzalex-daratumumab-anticorps-monoclonal-en-association
https://www.has-sante.fr/portail/jcms/c_2808583/fr/darzalex-en-association
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
treatment outcome
antineoplastic combined chemotherapy protocols
daratumumab
daratumumab
antineoplastic agents
antineoplastic agents
multiple myeloma
disease-free survival
survival analysis
adult
daratumumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2808595/fr/darzalex-daratumumab-anticorps-monoclonal-monotherapie
https://www.has-sante.fr/portail/jcms/c_2808595/fr/darzalex-monotherapie
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
adult
multiple myeloma
recurrence
daratumumab
daratumumab
daratumumab
antineoplastic agents
antineoplastic agents
treatment outcome
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2900188/fr/crysvita
2019
false
false
false
France
French
treatment outcome
burosumab
orphan drug production
familial hypophosphatemic rickets
infant
child
adolescent
injections, subcutaneous
familial hypophosphatemic rickets
evaluation of the transparency committee
burosumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1237
2019
false
false
false
false
France
canakinumab
injections, subcutaneous
myocardial infarction
treatment outcome
C-reactive protein
anti-inflammatory agents
anti-inflammatory agents
cardiovascular diseases
stroke
atherosclerosis
critical appraisal or critical reading
myocardial infarction
canakinumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2908438/fr/tremfya
2019
false
true
false
false
France
Injectable Solution Dosage Form
guselkumab
antibodies, monoclonal
Pre-filled Pen Syringe
psoriasis
adult
insurance, health, reimbursement
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2908478/fr/imfinzi
https://www.has-sante.fr/portail/jcms/c_2908478/fr/imfinzi-durvalumab-anticorps-monoclonal
2019
false
true
false
false
France
infusions, intravenous
carcinoma, non-small-cell lung
durvalumab
adult
antineoplastic agents
treatment outcome
CD274 protein, human
guidelines for drug use
evaluation of the transparency committee
durvalumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2908652/fr/aimovig
2019
false
true
false
false
France
treatment outcome
insurance, health, reimbursement
erenumab
erenumab
injections, subcutaneous
migraine disorders
adult
erenumab
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
---
TECENTRIQ (atezolizumab) - Risk of Immune-Related Myositis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69274a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
atezolizumab
Metastatic Urothelial Carcinoma
carcinoma, non-small-cell lung
urinary bladder neoplasms
myositis
antineoplastic agents
infusions, intravenous
atezolizumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/emgality
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
galcanezumab
galcanezumab
adult
migraine disorders
injections, subcutaneous
calcitonin gene-related peptide
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
galcanezumab
antibodies, monoclonal
antibodies, monoclonal
---
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69402a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
daratumumab
Hepatitis B reactivation
hepatitis B
continuity of patient care
virus activation
hepatitis b virus
mass screening
hepatitis B
antineoplastic agents
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2963343/fr/mylotarg
2019
false
true
false
false
France
French
evaluation of the transparency committee
gemtuzumab ozogamicin
survival analysis
infusions, intravenous
leukemia, myeloid, acute
Antineoplastic Agents, Immunological
gemtuzumab ozogamicin
CD33 protein, human
adult
adolescent
orphan drug production
treatment outcome
Powder for infusion solution (qualifier value)
drug therapy, combination
daunorubicin
cytarabine
aminoglycosides
antibodies, monoclonal
antibodies, monoclonal
aminoglycosides
sialic acid binding ig-like lectin 3
aminoglycosides
antibodies, monoclonal
Gemtuzumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
fremanezumab
fremanezumab
product surveillance, postmarketing
adult
migraine disorders
aged
injections, subcutaneous
pregnancy
breast feeding
calcitonin gene-related peptide
fremanezumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ansm.sante.fr/actualites/lansm-octroie-une-atu-de-cohorte-dextension-dindication-pour-lutilisation-de-tecentriq-atezolizumab-dans-le-cancer-bronchique-a-petites-cellules
2019
false
false
false
France
French
bronchial neoplasms
small cell lung carcinoma
atezolizumab
antineoplastic agents
atezolizumab
drug information
adult
antineoplastic combined chemotherapy protocols
guidelines for drug use
continuity of patient care
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2965862/fr/tecentriq
2019
false
true
false
false
France
Urothelial Carcinoma
urologic neoplasms
antineoplastic agents
atezolizumab
adult
carcinoma, transitional cell
carcinoma, non-small-cell lung
evaluation of the transparency committee
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2967184/fr/darzalex
2019
false
false
false
France
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
infusions, intravenous
antineoplastic agents
daratumumab
Bortezomib
melphalan
prednisone
survival analysis
treatment outcome
evaluation of the transparency committee
Darzalex
daratumumab
antibodies, monoclonal
daratumumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2969189/fr/ilaris
2019
false
false
false
France
Still's disease, Adult-Onset
canakinumab
canakinumab
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2973363/fr/takhzyro
2019
false
false
false
France
French
lanadelumab
lanadelumab
injections, subcutaneous
treatment outcome
angioedemas, hereditary
recurrence
adolescent
adult
aged
orphan drug production
evaluation of the transparency committee
lanadelumab
antibodies, monoclonal
---
https://www.louvainmedical.be/fr/article/les-biotherapies-dans-le-traitement-du-psoriasis-modere-severe
2019
false
false
false
Belgium
biological therapy
psoriasis
antibodies, monoclonal
apremilast
biological therapy
continuity of patient care
journal article
thalidomide
thalidomide
---
https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
risankizumab
Product containing only risankizumab in parenteral dose form (medicinal product form)
risankizumab
risankizumab
antibodies, monoclonal
antibodies, monoclonal
---
https://ansm.sante.fr/informations-de-securite/darzalex-v-daratumumab-risque-de-reactivation-du-virus-de-lhepatite-b
2019
false
false
false
France
French
hepatitis B
daratumumab
Hepatitis B reactivation
virus activation
hepatitis B
mass screening
hepatitis B
pharmacovigilance note
guidelines for drug use
daratumumab
continuity of patient care
risk
hepatitis b virus
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00428
2019
false
false
false
Canada
French
drug information
drug approval
canada
dinutuximab
dinutuximab
treatment outcome
injections, intravenous
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
child
neuroblastoma
antibodies, monoclonal
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00429
2019
false
false
false
Canada
French
drug evaluation
burosumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
cemiplimab
cemiplimab
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Locally Advanced Skin Squamous Cell Carcinoma
carcinoma, squamous cell
skin neoplasms
infusions, intravenous
programmed cell death 1 receptor
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
Metastatic Skin Squamous Cell Carcinoma
cemiplimab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ansm.sante.fr/actualites/modification-des-conditions-de-prescription-et-delivrance-de-certaines-biotherapies-utilisees-dans-le-traitement-de-maladies-inflammatoires-chroniques-en-rhumatologie-gastroenterologie-dermatologie-ophtalmologie
2019
false
false
false
France
French
drug prescriptions
drug information
Adalimumab
Etanercept
golimumab
Certolizumab Pegol
anakinra
interleukin 1 receptor antagonist protein
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3080470/fr/keytruda-tete-et-cou-2eme-ligne
2019
false
false
false
France
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
pembrolizumab
adult
neoplasm recurrence, local
neoplasm metastasis
infusions, intravenous
Antineoplastic Agents, Immunological
programmed cell death 1 receptor
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3081881/fr/praluent
https://www.has-sante.fr/jcms/pprd_2983646/fr/praluent
2019
false
false
false
France
French
evaluation of the transparency committee
drug therapy, combination
hypercholesterolemia
Atherosclerotic Cardiovascular Disease
adult
cardiovascular diseases
alirocumab
acute coronary syndrome
treatment outcome
insurance, health, reimbursement
alirocumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3096551/fr/simponi
2019
false
false
false
France
golimumab
drug therapy, combination
methotrexate
child
arthritis, juvenile
injections, subcutaneous
evaluation of the transparency committee
golimumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3098005/fr/crysvita
2019
false
false
false
France
burosumab
injections, subcutaneous
rickets, X-Linked hypophosphatemic
infant
child
adolescent
treatment outcome
insurance, health, reimbursement
burosumab
evaluation of the transparency committee
familial hypophosphatemic rickets
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3101051/fr/combo-stent
2019
France
health technology assessment
Monoclonal antibodies
antibodies, anti-idiotypic
stents
pharmacology
sirolimus
pharmacologist
antigens, CD34
extracellular matrix
antibodies, monoclonal
templates, genetic
monoclonal antibody
Monoclonal antibodies
---
https://www.has-sante.fr/jcms/p_3101057/fr/combo-plus-stent
2019
France
health technology assessment
extracellular matrix
templates, genetic
pharmacology
monoclonal antibody
Monoclonal antibodies
pharmacologist
stents
sirolimus
Drug-Eluting stents
antibodies, monoclonal
Monoclonal antibodies
antibodies, anti-idiotypic
antigens, CD34
stents
---
https://www.has-sante.fr/jcms/p_3097594/fr/cosentyx
2019
false
false
false
France
evaluation of the transparency committee
Cosentyx
secukinumab
antibodies, monoclonal
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1250
2019
false
false
false
false
Canada
critical appraisal or critical reading
bone density conservation agents
osteoporosis, postmenopausal
alendronate
bone density conservation agents
spinal fractures
spinal fractures
journal article
alendronate
osteoporotic fractures
female
romosozumab
antibodies, monoclonal
romosozumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3108955/fr/aimovig
2019
false
false
false
France
erenumab
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3113584/fr/tecentriq
2019
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
atezolizumab
antineoplastic agents
infusions, intravenous
atezolizumab
antineoplastic combined chemotherapy protocols
Bevacizumab
paclitaxel
carboplatin
adult
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
neoplasm metastasis
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/trogarzo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ibalizumab
ibalizumab
adult
hiv infections
anti-hiv agents
anti-hiv agents
ibalizumab
infusions, intravenous
CD4 Antigens
product surveillance, postmarketing
drug therapy, combination
aged
pregnancy
breast feeding
drug evaluation, preclinical
multiresistant HIV-1 infection
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3081878/fr/keytruda
2019
false
false
false
France
adult
melanoma
Adjuvant Chemotherapy
Antineoplastic Agents, Immunological
pembrolizumab
pembrolizumab
treatment outcome
infusions, intravenous
disease-free survival
recurrence
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3117564/fr/skyrizi
2019
false
false
false
France
treatment outcome
injections, subcutaneous
psoriasis
adult
Interleukin-23
risankizumab
evaluation of the transparency committee
risankizumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3117084/fr/keytruda
2019
false
false
false
France
pembrolizumab
pembrolizumab
evaluation of the transparency committee
Keytruda
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3119783/fr/tecentriq
2019
false
false
false
France
atezolizumab
atezolizumab
infusions, intravenous
adult
antineoplastic combined chemotherapy protocols
Albumin-Bound Paclitaxel
carboplatin
carcinoma, non-small-cell lung
bronchial neoplasms
neoplasm metastasis
evaluation of the transparency committee
Tecentriq
antibodies, monoclonal
---
https://www.prescrire.org/fr/3/31/58120/0/NewsDetails.aspx
2019
false
false
false
France
French
french abstract
olaratumab
coitus interruptus
antibodies, monoclonal
---
https://ansm.sante.fr/tableau-marr/pembrolizumab
2019
false
false
false
France
French
risk management
pembrolizumab
Infusion related reaction
immune system diseases
Drug-Related side effects and adverse reactions
patient education handout
pregnancy
continuity of patient care
drug monitoring
guideline
Antineoplastic Agents, Immunological
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2769366/fr/yervoy-ipilimumab-anticorps-monoclonal-melanome-1ere-et-2eme-ligne
2018
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
treatment outcome
Advanced Malignant Neoplasm
ipilimumab
infusions, intravenous
CTLA4 protein, human
BRAF Gene Mutation
melanoma
antineoplastic agents
antineoplastic agents
Ipilimumab
Ipilimumab
melanoma
antibodies, monoclonal
antibodies, monoclonal
CTLA-4 antigen
---
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65990a-fra.php
2018
false
false
false
Canada
French
pharmacovigilance note
infusions, intravenous
atezolizumab
risk
myocarditis
antineoplastic agents
atezolizumab
guidelines for drug use
continuity of patient care
drug monitoring
myocarditis
Drug-Related side effects and adverse reactions
Invasive Bladder Urothelial Carcinoma
urinary bladder neoplasms
myocarditis
signs and symptoms
patients guideline
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2825867/fr/keytruda-vessie-1ere-ligne
2018
false
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
urinary bladder neoplasms
Urothelial Neoplasm
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2829034/fr/opdivo
https://www.has-sante.fr/portail/jcms/c_2829034/fr/opdivo-nivolumab-anticorps-anti-pd1
2018
false
false
false
France
French
treatment outcome
evaluation of the transparency committee
infusions, intravenous
nivolumab
antineoplastic agents
antineoplastic agents
adult
carcinoma, squamous cell
upper aerodigestive tract neoplasms
disease progression
Cancer Progression
quality of life
survival analysis
guidelines for drug use
head and neck neoplasms
antibodies, monoclonal
Nivolumab
---
https://www.franceculture.fr/emissions/la-methode-scientifique/la-methode-scientifique-du-lundi-05-mars-2018
2018
false
false
false
France
French
radio broadcast
immunity
monoclonal antibody
immune state, nos
antibodies, monoclonal
---
https://www.ema.europa.eu/medicines/human/EPAR/Crysvita
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
burosumab
orphan drug production
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
familial hypophosphatemic rickets
infant
child
adolescent
injections, subcutaneous
product surveillance, postmarketing
continuity of patient care
familial hypophosphatemic rickets
drug interactions
drug evaluation, preclinical
burosumab
burosumab
antibodies, monoclonal
antibodies, monoclonal
Fibroblast Growth Factor-23
---
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-carcinome-urothelial
https://www.has-sante.fr/portail/jcms/c_2830777/fr/keytruda-pembrolizumab-anticorps-monoclonal-carcinome-urothelial
2018
false
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
pembrolizumab
treatment outcome
survival analysis
Urothelial Carcinoma
urologic neoplasms
infusions, intravenous
pembrolizumab
antineoplastic agents
antineoplastic agents
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2857791/fr/arzerra
2018
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
arzerra
ofatumumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2842284/fr/kyntheum
https://www.has-sante.fr/portail/jcms/c_2842284/fr/kyntheum-brodalumab-immunosuppresseur-inhibiteur-d-interleukines
2018
false
false
false
France
French
brodalumab
antibodies, monoclonal
brodalumab
treatment outcome
psoriasis
adult
injections, subcutaneous
Prefilled Syringe Dosage Form
receptors, interleukin-17
receptors, interleukin-17
IL17RA protein, human
insurance, health, reimbursement
evaluation of the transparency committee
guidelines for drug use
brodalumab
antibodies, monoclonal
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1190
2018
false
false
false
false
Canada
French
critical appraisal or critical reading
Acne fulminans
daratumumab
data collection
multiple myeloma
Myeloma
Induced fracture
dexamethasone
intractable
Myeloma
therapeutics
treaties
combined
multiple myeloma
international cooperation
antibodies, monoclonal
thalidomide
Lenalidomide
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1207
2018
false
false
false
false
Canada
French
critical appraisal or critical reading
Urothelial Carcinoma
Antineoplastic Agents, Immunological
survival analysis
urologic neoplasms
antineoplastic combined chemotherapy protocols
disease progression
programmed cell death 1 receptor
pembrolizumab
neoplasm recurrence, local
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
platinum compounds
comparative effectiveness research
immunotherapy
pembrolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat
---
https://ansm.sante.fr/informations-de-securite/keytruda-pembrolizumab-v-restriction-dindication-dans-le-traitement-des-patients-adultes-atteints-dun-carcinome-urothelial-localement-avance-ou-metastatique-ineligibles-a-une-chimiotherapie-a-base-de-cisplatine
2018
false
false
false
France
French
guidelines for drug use
pembrolizumab
pembrolizumab
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Urothelial Carcinoma
survival analysis
infusions, intravenous
antineoplastic agents
urologic neoplasms
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/informations-de-securite/tecentriq-r-atezolizumab-v-restriction-dindication-dans-le-traitement-des-patients-adultes-atteints-dun-carcinome-urothelial-localement-avance-ou-metastatique-ineligibles-a-une-chimiotherapie-a-base-de-cisplatine
2018
false
false
false
France
French
guidelines for drug use
atezolizumab
atezolizumab
infusions, intravenous
antineoplastic agents
adult
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Urothelial Carcinoma
urologic neoplasms
survival analysis
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2856039/fr/lartruvo
https://www.has-sante.fr/portail/jcms/c_2856039/fr/lartruvo-olaratumab-anticorps-monoclonal
2018
false
false
false
France
French
treatment outcome
orphan drug production
antineoplastic agents
adult
sarcoma
antineoplastic combined chemotherapy protocols
receptor, platelet-derived growth factor alpha
infusions, intravenous
olaratumab
evaluation of the transparency committee
Soft tissue sarcoma
guidelines for drug use
olaratumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2856045/fr/tecentriq-poumon
2018
false
false
false
France
French
atezolizumab
treatment outcome
antineoplastic agents
adult
aged
infusions, intravenous
B7-H1 Antigen
CD274 protein, human
carcinoma, non-small-cell lung
evaluation of the transparency committee
neoplasm metastasis
Locally Advanced Malignant Neoplasm
atezolizumab
antibodies, monoclonal
---
Aimovig erenumab
https://www.ema.europa.eu/medicines/human/EPAR/Aimovig
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
erenumab
erenumab
drug approval
europe
adult
migraine disorders
injections, subcutaneous
product surveillance, postmarketing
antibodies, monoclonal
antibodies, monoclonal
aged
drug interactions
pregnancy
chronic disease
drug evaluation, preclinical
erenumab
Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide Receptor Antagonists
---
https://www.has-sante.fr/portail/jcms/c_2869374/fr/repatha
2018
false
false
false
false
France
French
evaluation of the transparency committee
repatha
evolocumab
antibodies, monoclonal
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1198
2018
false
false
false
Canada
French
SOST protein, human
osteoporotic fractures
hip fractures
spinal fractures
treatment outcome
critical appraisal or critical reading
romosozumab
osteoporosis, postmenopausal
romosozumab
antibodies, monoclonal
romosozumab
genetic markers
bone morphogenetic proteins
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/c_2863559/fr/yervoy-melanome-ipilimumab
2018
false
France
French
evaluation of the transparency committee
Advanced Malignant Neoplasm
guidelines for drug use
adolescent
Ipilimumab
Ipilimumab
ipilimumab
infusions, intravenous
antibodies, monoclonal
antibodies, monoclonal
melanoma
treatment outcome
neoplasm metastasis
survival analysis
---
TECENTRIQ (atezolizumab) - Risk of Immune-Related Nephritis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67782a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
infusions, intravenous
atezolizumab
continuity of patient care
nephritis
nephritis
antineoplastic agents
urologic neoplasms
carcinoma, non-small-cell lung
nephritis
atezolizumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2870207/fr/opdivo
2018
false
false
false
false
France
French
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=43980
2018
false
false
false
France
French
drug information
Neural crest tumor
dinutuximab
relative
Neuroblastoma
risk
superior
beta, nos
neuroblastoma
Induced fracture
transitory
neuroblastoma, nos
treaties
Epidermolytic acanthoma
therapeutics
financial support
high
neural crest tumor
international cooperation
adrenal gland neoplasms
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00385
2018
false
false
false
Canada
French
English
drug information
avelumab
avelumab
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00387
2018
false
false
false
Canada
French
English
drug information
guselkumab
drug evaluation
drug approval
canada
treatment outcome
product surveillance, postmarketing
guselkumab
injections, subcutaneous
interleukin-23 subunit p19
immunomodulators
immunomodulators
psoriasis
adult
guselkumab
antibodies, monoclonal
immunologic factors
immunologic factors
antibodies, monoclonal
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00394
2018
false
false
false
Canada
French
English
drug information
brodalumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2872662/fr/bavencio
2018
false
false
false
France
French
avelumab
avelumab
treatment outcome
orphan drug production
adult
Antineoplastic Agents, Immunological
carcinoma, merkel cell
infusions, intravenous
B7-H1 Antigen
neoplasm metastasis
evaluation of the transparency committee
survival analysis
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tildrakizumab
treatment outcome
drug approval
europe
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
aged
drug storage
drug evaluation, preclinical
tildrakizumab
tildrakizumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
guselkumab
guselkumab
guselkumab
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal
interleukin-23 subunit p19
arthritis, psoriatic
---
https://www.has-sante.fr/portail/jcms/c_2879791/fr/repatha
2018
false
false
false
France
hypercholesterolemia
dyslipidemias
injections, subcutaneous
evolocumab
treatment outcome
evaluation of the transparency committee
repatha
evolocumab
antibodies, monoclonal
evolocumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2842744/fr/keytruda-pembrolizumab-anticorps-anti-pd1
2018
false
false
false
France
French
guidelines for drug use
treatment outcome
pembrolizumab
pembrolizumab
infusions, intravenous
pembrolizumab
hodgkin disease
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
programmed cell death 1 receptor
recurrence
hematopoietic stem cell transplantation
transplantation, autologous
adult
Refractory Hodgkin Lymphoma
survival analysis
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
antibodies, monoclonal, humanized
Brentuximab Vedotin
---
http://www.sfendocrino.org/_images/mediatheque/articles/pdf/recommandations/2018_Immunotherapies%20/mced_94_bd.pdf
2018
false
false
false
France
French
immunotherapy
antibodies, monoclonal
consensus
continuity of patient care
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
protein kinase inhibitors
TOR Serine-Threonine kinases
adrenal glands
pituitary gland
metabolism
endocrine system diseases
diabetes mellitus
Hypophysitis
hypothyroidism
adrenal insufficiency
Hormone Measurement
hormones
Tyrosine Kinase Inhibitors
---
https://www.has-sante.fr/portail/jcms/c_2877053/fr/tremfya
https://www.has-sante.fr/portail/jcms/c_2877053/fr/tremfya-guselkumab-immunosuppresseur-inhibiteur-de-l-interleukine-23
2018
false
false
false
France
French
treatment outcome
guselkumab
guselkumab
adult
psoriasis
injections, subcutaneous
Interleukin-23
evaluation of the transparency committee
guidelines for drug use
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
durvalumab
durvalumab
durvalumab
carcinoma, non-small-cell lung
adult
aged
B7-H1 Antigen
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
bronchial neoplasms
antibodies, monoclonal
antibodies, monoclonal
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=695
2018
false
false
false
France
French
public health guidelines
hemorrhagic fever, ebola
hemorrhagic fever, ebola
health personnel
occupational exposure
Pre-Exposure Prophylaxis
Post-Exposure prophylaxis
ebola vaccines
antibodies, monoclonal
antiviral agents
ZMapp
Remdesivir
favipiravir
remdesivir
amides
pyrazines
alanine
alanine
ribonucleotides
---
http://www.academie-medecine.fr/anticorps-monoclonaux-en-oncologie-declencher-une-reponse-immunitaire-en-plus-de-la-reduction-tumorale-specifique/
2018
false
false
false
France
antibodies, monoclonal
neoplasms
antibodies, monoclonal
antibodies, monoclonal
journal article
---
http://www.academie-medecine.fr/effets-endocriniens-et-metaboliques-des-immunotherapies-anticancereuses-dapres-les-recommandations-de-la-societe-francaise-dendocrinologie/
2018
false
false
false
France
Antineoplastic Agents, Immunological
antibodies, monoclonal
CTLA4 protein, human
thyroid diseases
Hypophysitis
Adrenalitis
adrenal gland diseases
diabetes mellitus
programmed cell death 1 receptor
B7-H1 Antigen
neoplasms
continuity of patient care
journal article
immunotherapy
CTLA-4 antigen
---
http://www.academie-medecine.fr/histoire-des-anticorps-therapeutiques/
2018
false
false
false
France
antibodies, monoclonal
journal article
---
https://www.has-sante.fr/portail/jcms/c_2885795/fr/keytruda
2018
false
false
false
France
Antineoplastic Agents, Immunological
pembrolizumab
melanoma
adult
carcinoma, non-small-cell lung
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal, humanized
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
lanadelumab
lanadelumab
lanadelumab
orphan drug production
adolescent
adult
angioedemas, hereditary
injections, subcutaneous
plasma kallikrein
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical
lanadelumab
lanadelumab
antibodies, monoclonal
antibodies, monoclonal
---
https://medicalforum.ch/fr/detail/doi/fms.2018.08011/
2018
false
false
false
Switzerland
journal article
blood group antibody di a
blood group antibody lu a
blood group antibody bx a
blood group antibody le bh
blood group antibody cr3
blood group antibody yk a
blood group antibody pt a
blood group antibody pr a
blood group antibody le x
blood group antibody at a
blood group antibody au a
blood group antibody tg a
blood group antibody lw b
blood group antibody a x
blood group antibody mcc a
blood group antibody sk a
blood group antibody a1
blood group antibody en afs
blood group antibody rh a
blood group antibody rd a
blood group antibody nijhuis
blood group antibody an a
blood group antibody xg a
blood group antibody s1a
blood group antibody rb a
blood group antibody be a
blood group antibody th a
blood group antibody mt a
blood group antibody kn a
blood group antibody wr a
blood group antibody li a
blood group antibody je a
blood group antibody sw a
blood group antibody le bl
blood group antibody wk a
blood group antibody dh a
blood group antibody m a
blood group antibody jn a
blood group antibody fy a
blood group antibody hg a
blood group antibody es a
blood group antibody lan
blood group antibody m'
blood group antibody pr a
blood group antibody gy a
blood group antibody jc a
infectious disease, nos
blood group antibody cs a
blood group antibody a.m.
blood group antibody r1a
Infections
blood group antibody go a
blood group antibody ht a
blood group antibody cl a
blood group antibody m1a
blood group antibody en akt
blood group antibody 'n'
blood group antibody a2
blood group antibody c
blood group antibody dr a
Infectious disease
blood group antibody le a
blood group antibody ol a
blood group antibody vr
bezlotoxumab
blood group antibody le c
blood group antibody fr a
blood group antibody sd a
blood group antibody os a
blood group antibody re a
blood group antibody yt a
blood group antibody en afr
blood group antibody zt a
blood group antibody do a
blood group antibody en ats
blood group antibody or a
blood group antibody le d
blood group antibody chr a
antibodies
blood group antibody lw a
blood group antibody le ns
blood group antibody kp a
blood group antibody tj a
blood group antibody a3
blood group antibody ls a
blood group antibody bg a
blood group antibody wd a
blood group antibody sc2
blood group antibody tr a
blood group antibody co a
blood group antibody n a
blood group antibody js a
blood group antibody mo a
blood group antibody u1a
blood group antibody jo a
therapeutics
blood group antibody rh42
blood group antibody ri a
blood group antibody ch a
blood group antibody jk a
blood group antibody a1 le d
antibody, nos
blood group antibody a1 le b
blood group antibody sf a
blood group antibody vg a
blood group antibody le b
blood group antibody yh a
blood group antibody bp a
blood group antibody a.m.
blood group antibody er a
blood group antibody c
blood group antibody ok a
blood group antibody le s
blood group antibody mi a
blood group antibody rg a
blood group antibody st a
blood group antibody jr a
blood group antibody in a
blood group antibody ny a
blood group antibody to a
antibodies, monoclonal
antibodies, neutralizing
---
https://www.has-sante.fr/portail/jcms/c_2893489/fr/simponi
https://www.has-sante.fr/portail/jcms/c_2893489/fr/simponi-golimumab-anti-tnf
2018
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
golimumab
golimumab
injections, subcutaneous
child
Polyarticular juvenile idiopathic arthritis
arthritis, juvenile
guidelines for drug use
tumor necrosis factor-alpha
antibodies, monoclonal
Tumor Necrosis Factor Inhibitors
---
https://www.has-sante.fr/portail/jcms/c_2894915/en/opdivo
2018
false
false
false
France
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
https://ansm.sante.fr/tableau-marr/atezolizumab
2018
false
false
false
France
French
atezolizumab
atezolizumab
atezolizumab
Drug-Related side effects and adverse reactions
risk management
scientific and technical information
patient education handout
Drug-Related side effects and adverse reactions
signs and symptoms
antineoplastic agents
antineoplastic agents
immune system diseases
immune system diseases
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2896995/en/opdivo
2018
false
false
false
France
antineoplastic agents
infusions, intravenous
nivolumab
evaluation of the transparency committee
antibodies, monoclonal
Nivolumab
---
https://ansm.sante.fr/tableau-marr/nivolumab
2018
false
false
false
France
French
risk management
immune system diseases
nivolumab
Drug-Related side effects and adverse reactions
guidelines for drug use
antineoplastic agents
immune system diseases
Drug-Related side effects and adverse reactions
summary of product characteristics
patient education handout
Drug-Related side effects and adverse reactions
antibodies, monoclonal
Nivolumab
---
https://pharmacomedicale.org/medicaments/par-specialites/item/recepteurs-membranaires
2018
false
true
false
France
Antineoplastic Agents, Immunological
antigens, neoplasm
vascular endothelial growth factors
receptor, erbB-2
Tyrosine Kinase Inhibitors
drug information
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/c_2806295/fr/ilaris-canakinumab-inhibiteur-de-l-interleukine-1
2018
false
true
false
France
guidelines for drug use
adult
adolescent
child
insurance, health, reimbursement
treatment outcome
periodic fever, familial, autosomal dominant
hyperimmunoglobulinemia D
familial mediterranean fever
injections, subcutaneous
canakinumab
evaluation of the transparency committee
interleukin inhibitors
Interleukin-1beta
canakinumab
mevalonate kinase deficiency
antibodies, monoclonal
fever
hereditary autoinflammatory diseases
---
https://www.has-sante.fr/portail/jcms/c_2780761/fr/keytruda
2017
false
false
false
France
French
evaluation of the transparency committee
Keytruda
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/medicines/human/EPAR/Kyntheum
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
brodalumab
antibodies, monoclonal
brodalumab
drug approval
europe
treatment outcome
psoriasis
adult
injections, subcutaneous
Prefilled Syringe Dosage Form
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
receptors, interleukin-17
receptors, interleukin-17
IL17RA protein, human
brodalumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2792203/fr/zinplava
2017
false
false
false
France
French
antibodies, monoclonal
treatment outcome
antibodies, neutralizing
adult
bezlotoxumab
toxB protein, clostridium difficile
infusions, intravenous
recurrence
aged
immunocompromised host
evaluation of the transparency committee
Clostridium difficile infection
drug therapy, combination
anti-bacterial agents
clostridium infections
Clostridioides difficile
clostridium infections
vancomycin
metronidazole
At increased risk for relapse (finding)
risk
clostridium infections
diarrhea
Clostridium difficile diarrhea (disorder)
bezlotoxumab
bacterial proteins
bacterial toxins
---
